Drugs / PCV24 formulation 2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06675032 | Apr 2024 → May 2025 overdue | pneumococcal infection | Shanghai Reinovax Biologics Co.,LTD | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV24 formulation 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06675032 ↗ |
| Modality | Vaccine | “24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 2” NCT06675032 ↗ |